What question did this study set out to answer?

To evaluate the effects of mitapivat on cardiomyopathy in a β-thalassemia mouse model.

December 8, 2025Blood

Long-term mitapivat treatment improves inflammatory pro-fibrotic cardiomyopathy in a murine model of β-thalassemia.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial improved inflammatory fibers and metabolomic profiles in β-thalassemia mice, suggesting cardiomyopathy mitigation through mitapivat.

To evaluate the effects of mitapivat on cardiomyopathy in a β-thalassemia mouse model.
Utilized male Hbb3th+ mice compared to wild-type controls.
Administered mitapivat from 2 months to assess impacts at 8 and 12 months.
Conducted metabolomic, lipidomic, and proteomic profiling of cardiac tissue.
Mitapivat treatment resulted in a significant increase in hemoglobin levels.
Normalization of glycolytic and TCA cycle intermediates was observed in treated mice.
Mitapivat reduced activation of pro-inflammatory pathways and improved heart lipid profiles.

Riccardi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial improved inflammatory fibers and metabolomic profiles in β-thalassemia mice, suggesting cardiomyopathy mitigation through mitapivat.